Cero Therapeutics Holdings Divestiture to SRX Global Inc. for $10.8M
CERo Therapeutics Holdings, Inc. entered into a definitive agreement to sell its wholly owned operating subsidiary, CERo Therapeutics, Inc., to SRX Global Inc. The consideration includes $1 million in SRX common stock, the assumption of approximately $1.562 million in liabilities, and the forgiveness of a senior secured promissory note with an outstanding balance of approximately $8.25 million. The agreement includes a 30-day 'go-shop' period allowing the company to solicit superior proposals.
- Value
- $10.8M
- Counterparty
- SRX Global Inc.